A Single Arm Phase II Trial of Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant Relapse
Phase of Trial: Phase II
Latest Information Update: 15 May 2019
Price : $35 *
At a glance
- Drugs Azacitidine (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
- 13 May 2019 Planned End Date changed from 1 Nov 2019 to 1 Nov 2020.
- 13 May 2019 Planned primary completion date changed from 1 Nov 2019 to 1 Nov 2020.
- 26 Oct 2018 Planned End Date changed from 1 Nov 2018 to 1 Nov 2019.